Abstract
The purpose of the study was to evaluate changes in best corrected visual acuity, central retinal thickness, area and flow in the neovascular membrane and to compare therapeutic outcomes from baseline in patients who received three doses of Beovu (brolucizumab) at three-month follow-up. Material and methods: A prospective observational study conducted at the Prof. K. Gibiński University Clinical Center of the Medical University of Silesia in Katowice. Eight patients with exudative form of age-related macular degeneration (AMD) were observed. Results: The mean best corrected visual acuity (BCVA) outcome increased with each subsequent visit. The mean central retinal thickness (CRT) result also improved (decreased) with each subsequent visit, except for the last measurement. A statistically significant change in neovascular membrane area was observed after the first injection. In further treatment, the membrane area underwent changes that were not statistically significant. A statistically significant change in neovascular membrane flow was demonstrated after the first and second injections. Discussion: Our study confirmed the efficacy of brolucizumab in the treatment of patients with exudative AMD in terms of improvements in best corrected visual acuity (BCVA), central retinal thickness (CRT), neovascular membrane area, and neovascular membrane flow area.
Highlights
Age-related macular degeneration (AMD) is a chronic, progressive degenerative disease of the macula that mainly affects the elderly population and leads to impaired central vision [1]
Measurements were made on the day of each injection and seven days after intravitreal injection
Brolucizumab is an innovative anti-vascular endothelial growth factor (VEGF) molecule that has been used to treat the exudative form of age-related macular degeneration
Summary
Age-related macular degeneration (AMD) is a chronic, progressive degenerative disease of the macula that mainly affects the elderly population and leads to impaired central vision [1]. AMD is the third cause of blindness in the world, after cataracts and glaucoma, while in developed countries it is the main cause [2]. There are dry and exudative forms of AMD. The pathomechanism of exudative AMD is complex and not fully understood. Retinal and choroidal hypoxia may cause dysregulation of vascular endothelial growth factor (VEGF) production by the retinal pigment epithelium (RPE). Growth of abnormal vessels is promoted, mainly from the choroid, and much less frequently from the retina [3]. Regular intravitreal administration of anti-VEGF agents, as a standard treatment for exudative AMD, significantly improves patient prognosis [4].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Environmental Research and Public Health
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
